InvestSMART

CSL Limited (ASX: CSL) - Announcements

Current share price for CSL : $203.340 1.2 (0.59%)+

ASX company news and announcements for CSL Limited (CSL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All CSL Limited (CSL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than CSL Limited (CSL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for CSL Limited (CSL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$97,181 Company Secretary Appointment/Resignation 21 Dec 2017 9:31AM $141.620 $202.510 risen by 43%
$97,181 CSL Appoints New Directors 13 Dec 2017 8:39AM $140.610 $202.510 risen by 44.02%
$97,181 Appendix 3B 5 Dec 2017 3:30PM $144.350 $202.510 risen by 40.29%
$97,181 R&D Investor Briefing 5 Dec 2017 8:46AM $145.310 $202.510 risen by 39.36%
$97,181 PGC: Acquisition of Immunohaematology Business 1 Dec 2017 11:21AM $145.750 $202.510 risen by 38.94%
$97,181 Notice of Research & Development Investor Briefing 30 Nov 2017 9:05AM $145.970 $202.510 risen by 38.73%
$97,181 Appendix 3B 14 Nov 2017 1:57PM $140.960 $202.510 risen by 43.66%
$97,181 Appendix 3B 24 Oct 2017 1:57PM $139.820 $202.510 risen by 44.84%
$97,181 Change of Director's Interest Notice 20 Oct 2017 2:28PM $139.180 $202.510 risen by 45.50%
$97,181 Final Director's Interest Notice Appendix 3Z 18 Oct 2017 3:29PM $141.540 $202.510 risen by 43.08%
$97,181 Results of 2017 Annual General Meeting 18 Oct 2017 3:27PM $141.540 $202.510 risen by 43.08%
$97,181 CEO's AGM Presentation 18 Oct 2017 9:56AM $138.950 $202.510 risen by 45.74%
$97,181 Chairman's Address to Shareholders 18 Oct 2017 9:52AM $138.950 $202.510 risen by 45.74%
$97,181 New Debt Facilities 5 Oct 2017 9:58AM $133.290 $202.510 risen by 51.93%
$97,181 Change to Company Details 15 Sep 2017 4:42PM $130.960 $202.510 risen by 54.64%
$97,181 FDA Approves Privigen for CIDP Indication 15 Sep 2017 9:17AM $131.250 $202.510 risen by 54.29%
$97,181 Retirement of Director 15 Sep 2017 8:56AM $131.250 $202.510 risen by 54.29%
$97,181 Annual Report to Shareholders 15 Sep 2017 8:54AM $131.250 $202.510 risen by 54.29%
$97,181 Notice of AGM/Proxy Form & Shareholder Questions 15 Sep 2017 8:47AM $131.250 $202.510 risen by 54.29%
$97,181 Appendix 4G - Key to Disclosures 15 Sep 2017 8:32AM $131.250 $202.510 risen by 54.29%
$97,181 Appendix 3B (Amended) 13 Sep 2017 9:01AM $132.610 $202.510 risen by 52.71%
$97,181 Appendix 3B 12 Sep 2017 2:25PM $132.845 $202.510 risen by 52.44%
$97,181 Final share buy-back notice - Appendix 3F 5 Sep 2017 10:42AM $129.960 $202.510 risen by 55.82%
$97,181 Final share buy-back notice - Appendix 3F 5 Sep 2017 8:31AM $130.460 $202.510 risen by 55.23%
$97,181 Daily share buy-back notice - Appendix 3E 5 Sep 2017 8:30AM $130.460 $202.510 risen by 55.23%

701 - 725 of 1207 results

Page 29 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.